ZIOPHARM Oncology Inc (NASDAQ:ZIOP) closed at $3.83 on Friday

750

Dallas, Texas 11/18/2013 (Financialstrend) – In Friday’s trading session, ZIOPHARM Oncology Inc (NASDAQ:ZIOP) rose by 9.43%. The shares opened at a price of $3.59, which touched the intraday high of $3.88 and headed to a close of $3.83. Around 1.68 million exchanged hands over the trading day and an average volume of 1.61 million shares were traded over a 30 day period. The 52-week low of ZIOPHARM Oncology Inc (NASDAQ:ZIOP) shares is $1.49 and its 52-week high is $5.95. ZIOPHARM Oncology Inc (NASDAQ:ZIOP) has a market capitalization of $375.27 million.                                        

About the company

ZIOPHARM Oncology Inc (NASDAQ:ZIOP) was incorporated on 16 May 2005. It  is a bio-technology company. it employs gene-expression & control-technology to deliver deoxyribonucleic-acid for cancer treatment. Its technology employsthe  Intrexon Corporation’s RheoSwitch Therapeutic-System to turn on & off &  precisely modulate, gene-expression at the cancer-site to improve the therapeutic-index.

As of 18 October 2013, the company’s technology was under evaluation in Phase-II clinical-studies of the immune-system cytokine interleukin-12 for treating breast cancer & advanced melanoma. It is also developing small-molecules as a potential cancer therapeutic.

In partnership with Intrexon, ZIOPHARM Oncology Inc (NASDAQ:ZIOP) is developing 2  clinical-stage DNA-therapeutics & is exploring numerous applications for this same revolutionary-technology in the lab. This includes the controlled-production in the body of therapeutic-antibodies, immune-toxins & protein decoys. ZIOPHARM Oncology Inc (NASDAQ:ZIOP) has multiple programs under its development. it also expects to file a minimum of 8 different IND applications right through to the year 2015. The recent data that has been presented at the 2013 AACR/NCI/EORTC meeting by ZIOPHARM Oncology Inc (NASDAQ:ZIOP) highlighted the potential use of skeletal-muscle as the embedded -controllable bioreactor. This will be used  to generate the therapeutics for various tumor targeted therapy of single / multiple RTS®-regulated cancer-immunotherapies which have the potential to be translated into an effective clinical regimen in cancer treatment.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.